Biotechnology firm Enveric Biosciences (NASDAQ:ENVB) revealed additional preclinical findings reinforcing the non-hallucinogenic nature of its primary drug candidate, EB-003. The company aims to treat psychiatric and neurological disorders by preserving the therapeutic benefits of neuroplasticity without inducing a hallucinatory experience.
